Kelley Kozma, DO
Hematology & Oncology · Stuart, FLNPI 1518168202
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $416 of the $604 with a category attached, or 68.9%. 11 manufacturers reported payments, led by Johnson & Johnson at 36.6% of the total. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 17 payments — averaging $35.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$221
- Gilead$70
- Takeda Pharmaceuticals U.S.A., Inc.$65
- Pfizer$55
- G1 Therapeutics, Inc.$44
- Novartis$37
- plus $112 from 5 others
Across 4 payments — averaging $15,238 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$35K
- Astrazeneca UK Limited$20K
- AstraZeneca$6K
- Amgen$480
What the payments were for
- Food & beverage$41669%
- Education$18831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 3 | $221 |
| Gilead | 1 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $65 |
| Pfizer | 3 | $55 |
| G1 Therapeutics, Inc. | 2 | $44 |
| Novartis | 2 | $37 |
| Daiichi Sankyo Inc. | 1 | $30 |
| Amgen | 1 | $29 |
| Genentech USA, Inc. | 1 | $23 |
| Bristol Myers Squibb | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$604 in reported general payments places this provider in the 20th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 175 | $3,767 |
| Anastrozole | 76 | $1,730 |
| Prochlorperazine Maleate | 31 | $883 |
| Ondansetron OdtOndansetron | 30 | $841 |
| Pantoprazole Sodium | 23 | $270 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $212 |
| Gabapentin | 15 | $193 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $162 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $134 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $125 |
| Allopurinol | 28 | $103 |
| Prednisone | 15 | $52 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Stuart
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.